GlassScriptPhysician profile
Alfred O Moon
NPI 1396953105
$9,127.08
in general payments reported to CMS, 2019-2025
37 companies · $2,225 in 2025
The $2,225 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,635 · 2020: $351 · 2021: $813 · 2022: $1,069 · 2023: $1,563 · 2024: $1,471 · 2025: $2,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,147 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,146.91 |
| Education | $112.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,035.03 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $985.65 | 2019-2025 | Tezspire, Otezla, Repatha |
| Regeneron Healthcare Solutions, INC. | $956.63 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $919.88 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Pfizer INC. | $824.15 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $818.10 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Genzyme Corporation | $782.79 | 2023-2025 | |
| Optinose US, INC. | $519.97 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $237.55 | 2022-2025 | Orladeyo |
| Csl Behring | $206.47 | 2019-2025 | Haegarda, Andembry |
| Novartis Pharmaceuticals Corporation | $179.58 | 2025 | |
| Shire North American Group INC | $161.94 | 2019 | |
| Genentech USA, INC. | $155.02 | 2021-2024 | Xolair |
| Aimmune Therapeutics, INC. | $139.69 | 2022 | |
| Kaleo, INC. | $137.99 | 2020-2024 | Auvi-Q |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $112.71 | 2025 | |
| Pharming Healthcare, INC. | $107.72 | 2023-2025 | Ruconest |
| Cycle Pharmaceuticals INC | $99.96 | 2025 | Sajazir |
| Incyte Corporation | $91.85 | 2021-2023 | Opzelura |
| Alk-Abello, INC | $87.44 | 2019-2025 | Neffy |
| Grifols USA, LLC | $81.27 | 2022-2025 | Xembify |
| Novo Nordisk INC | $80.66 | 2019-2024 | Wegovy |
| Ionis Pharmaceuticals, INC. | $48.87 | 2025 | Dawnzera |
| Bausch Health US, LLC | $45.11 | 2019 | |
| Genentech, INC. | $38.50 | 2019 | |
| Merck Sharp & Dohme LLC | $36.23 | 2019-2021 | |
| Greer Laboratories, INC. | $34.16 | 2025 | Oralair |
| Janssen Pharmaceuticals, INC | $27.90 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.20 | 2019 | |
| Abbvie INC. | $21.87 | 2025 | |
| Irhythm Technologies, INC. | $21.64 | 2019 | |
| Ibsa Pharma INC. | $20.74 | 2019 | |
| Organon LLC | $20.26 | 2025 | Vtama |
| Therapeuticsmd, INC. | $19.28 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.78 | 2019 | |
| Sanofi Pasteur INC. | $17.58 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfred Moon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.